Amyndas is a fast-developing innovator and emerging leader in the field of "complement therapeutics, " with a compelling investment proposition, a highly promising pipeline and attractive M&A/licensing opportunities. The company is committed to developing the most advanced therapies to treat inflammatory disorders, in particular orphan diseases and conditions representing areas of unmet medical need for which patients need better and safer therapies.
It has programs in Transplantation, the rare hemolytic disease Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 glomerulonephritis, Periodontitis, Age-Related Macular Degeneration, Hemodialysis and Ischemia/Reperfusion Injuries.
It has programs in Transplantation, the rare hemolytic disease Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 glomerulonephritis, Periodontitis, Age-Related Macular Degeneration, Hemodialysis and Ischemia/Reperfusion Injuries.
Services
Dr. Lambris, the Dr. Ralph and Sallie Weaver Professor of Research Medicine in the Department of Pathology & Laboratory Medicine at the University of Pennsylvania, is an established authority in the field of innate immunity. Using complement as a model system, he applies ideas and methods embodied in engineering, computer science, physics, chemistry, biomedicine, and other fields to address today's challenges in biosciences.
Reviews
Be the first to review Amyndas Pharmaceuticals.
Write a Review
